Cas:283173-83-1 1-(4-Bromo-2-fluorobenzyl)pyrrolidine manufacturer & supplier

Chemical Name:1-(4-Bromo-2-fluorobenzyl)pyrrolidine

CAS.NO:283173-83-1

Synonyms:Pyrrolidine, 1-[(4-bromo-2-fluorophenyl)methyl]-;1-(4-Bromo-2-fluorobenzyl)pyrrolidine;PC7159

Molecular Formula:C₁₁H₁₃BrFN

Molecular Weight:258.130

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:281.6±25.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.574

PSA:3.24000

Exact Mass:257.021545

LogP:3.00

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Pyrrolidine, 1-[(4-bromo-2-fluorophenyl)methyl]- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,PC7159 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,PC7159 Use and application,PC7159 technical grade,usp/ep/jp grade.

Related News: Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. 1-(4-Bromo-2-fluorobenzyl)pyrrolidine manufacturer The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 1-(4-Bromo-2-fluorobenzyl)pyrrolidine supplier The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 1-(4-Bromo-2-fluorobenzyl)pyrrolidine vendor Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. 1-(4-Bromo-2-fluorobenzyl)pyrrolidine factory In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.